As Hu­mi­ra sales fall, Ab­b­Vie fo­cus­es on Skyrizi, Rin­voq growth, eyes ex­ter­nal com­bo strate­gies 

Ab­b­Vie said Hu­mi­ra, one of the world’s biggest-sell­ing drugs, still brought in $3.5 bil­lion in sales in the third quar­ter, though the 36% dip in year-over-year rev­enue was in line with Wall Street pro­jec­tions now that rough­ly 10 biosim­i­lars have en­tered the mar­ket.

In its third-quar­ter earn­ings call on Fri­day, the phar­ma gi­ant em­pha­sized the per­for­mance of its next-gen­er­a­tion im­munol­o­gy drugs, Rin­voq and Skyrizi, cit­ing their growth as the com­pa­ny raised its full-year rev­enue guid­ance by $600 mil­lion on Fri­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER